132.37
+3.24
+2.51%
+3.24
+2.51%
MORE ON BIPSX
DETAILS
| Symbol | Value ($) |
|---|---|
| Morningstar Rating | |
| Previous Close | 129.13 |
| Category | Health |
| Net Assets | 12.19 Mil |
| Yield | 0.00% |
| Morningstar Risk | High |
| Morningstar Return | High |
- Last NAV update 6/18/2013 10:56 PM ET
INVESTMENT OBJECTIVE
| NA |
|---|
| The investment seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) the daily performance of the Dow Jones U.S. BiotechnologySM Index. The fund invests in securities and derivatives that the adviser believes, in combination, should have similar daily return characteristics as one and one-half times (1.5x) the daily return of the index. The index measures the performance of the biotechnology sector of the U.S. equity market. It is non-diversified. |
CUMULATIVE PERFORMANCE OF $10,000
| 2009 | 2010 | 2011 | 2012 | 2013 | |
|---|---|---|---|---|---|
| Return | 2.15% | 5.31% | 7.44% | 64.18% | 50.03% |
| Value ($) | 10,215.05 | 10,756.98 | 11,556.98 | 18,974.18 | 28,466.65 |
- Year to date performance as of 6/18/2013 12:00 AM ET
MANAGEMENT & PURCHASE INFO
| Symbol | Value ($) |
|---|---|
| Fund Family | ProFunds |
| Fund Manager | Hratch Najarian |
| Tenure (Years) | 2 |
| Fund Status | Open |
| Minimum Initial Purchase | 15,000.00 |
| Minimum IRA Investment | 15,000.00 |
| Front Load | 0.00 |
| Expense Ratio | 2.73% |
PERFORMANCE
| Symbol | Value ($) |
|---|---|
| 1 Month | -8.91% |
| 3 Months | 20.79% |
| 1 Year | 87.95% |
| 3 Years* | 43.01% |
| 5 Years* | 21.97% |
- * Annualized returns
- Performance as of 6/18/2013 12:00 AM ET
PEER COMPARISON
| BIPSX | Health | |
|---|---|---|
| 5-Yr Return | 21.97% | 13.10% |
| Sharpe Ratio | 1.76 | 2.88 |
| Net Assets | 12.19 Mil | 517.54 Mil |
| Avg Market Cap | 30.59 Bil | 19.45 Bil |
| Avg P/E | 17.59 | 21.67 |
| Portfolio Turnover | 37 | 47 |
HOLDINGS
| Symbol | Value ($) |
|---|---|
| Stocks | 56.32% |
| Cash | 42.49% |
| Fixed Income | 0.00% |
| Other | 1.20% |
TOP 10 HOLDINGS
| NAME | % NET ASSETS |
|---|---|
| Amgen Inc | 10.13% |
| Gilead Sciences Inc | 9.23% |
| AbbVie Inc | 8.97% |
| Celgene Corporation | 6.48% |
| Biogen Idec Inc | 5.71% |
| Alexion Pharmaceuticals, Inc. | 2.83% |
| Regeneron Pharmaceuticals, Inc. | 2.03% |
| Life Technologies Corp | 1.72% |
| Vertex Pharmaceuticals | 1.49% |
| Biomarin Pharmaceutical, Inc. | 1.06% |
DATA PROVIDERS
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
RECENT QUOTES
WATCHLIST
You're not signed in
You’re not signed in to MSN Money, so you’re seeing the Watchlist that is tied to your computer. For a more consistent Watchlist experience, sign in to MSN Money.
Learn more
Sponsored by:
MARKET UPDATE
[BRIEFING.COM] The major averages ended higher across the board as the S&P 500 advanced 0.8%. Equities climbed steadily since the opening bell as investors prepared for tomorrow's policy decision from the Federal Reserve. Although chatter in recent w
...
More
MORE MARKET NEWS
Sponsored by:
INVESTING TIPS AND TOOLS